Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

Lancet

Volumn 349, Issue 9069, 1996, Pages 1857-1863

  Remuzzi, Giuseppe ^a   Ruggenenti, P ^b   Perna, A ^b   Mosconi, L ^b   Matalone, M ^b   Garini, G ^b   Salvadori, M ^b   Zoccali, C ^b   Scolari, F ^b   Maggiore, Q ^b   Tognoni, G ^b   Remuzzi, G ^b   Migone, L ^b   Marubini, E ^b   Del Favero, A ^b   Ideo, G ^b   Geraci, E ^b   Loi, U ^b   Arnoldi, F ^b   Gaspari, F ^b   Signorini, O ^b   Ferrari, S ^b   Guerini, E ^b   more..

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RAMIPRIL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 0030604561     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)11445-8     Document Type: Article

References (36)

1. 1 Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of haemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis. N Engl J Med 1982; 307: 652-59.
2. 2 Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981; 241: F85-93.
3. 3 Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-19.
4. 4 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
5. 5 Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-89.
6. 6 Parving HH, Andersen AR, Smidt UM, Swendsen PAA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; i: 1175-79.
7. 7 Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43.
8. 8 Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91.
9. 9 Lewis EJ, Hunsicker LG, Bain RP, Rohde ED. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62.
10. 10 Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effects of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38.
11. 11 Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10: 39-45.
12. 12 Morelli E, Loon N, Meye TW, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76-82.
13. 13 Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Remuzzi G. Effect of low-dose enalapril on glomerular size selectivity in human diabetic nephropathy. J Nephrol 1993; 6: 36-43.
14. 14 Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting-enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541-49.
15. 15 Remuzzi G. Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 1995; 4: 339-42.
16. 16 Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-94.
17. 17 Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986; 30: 488-96.
18. 18 Hirschberg R. Bioactivity of glomerular ultrafiltrate during heavy proteinuria may contribute to renal tubulo-interstitial lesions. J Clin Invest 1996; 98: 116-24.
19. 19 Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994; 5: 1273-78.
20. 20 Kamper AL, Straudgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure: a randomised controlled trial. Am J Hypertens 1992; 5: 423-30.
21. 21 Ihle BU, Whitworth JA, Shainfar S, Cnaon A, Kincaid-Smith PS, Becker GJ. Angiotensin converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double blind trial. Am J Kidney Dis 1996; 27: 489-95.
22. 22 Hannedouche T, Laudais P, Goldfarb B, et al. Randomized controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-37.
23. 23 Zucchelli P, Zuccalà A, Borghi M, et al. Long-term comparison between captopril and nifedipine in the progression of chronic renal insufficiency. Kidney Int 1992; 42: 452-58.
24. 24 Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
25. 25 Gruppo Italiano Studi Epidemiologici in Nefrologia (GISEN): a long-term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies. J Nephrol 1991; 3: 193-202.
26. 26 Haybittle JL. Repeated assessments of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-97.
27. 27 Erman A, Winkler J, Chen-Gal B, et al. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991; 9: 1057-62.
28. 28 Gaspari F, Perico N, Ruggenenti P, et al. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate in patients with normal or impaired renal function. J Am Soc Nephrol 1995; 6: 1-7.
29. 29 Rice EW. Improved biuret procedure for determination of urinary total proteins in clinical proteinuria. Clin Chem 1975; 21: 398-400.
30. 30 Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443-47.
31. 31 Conover WJ. Practical nonparametric statistics, 2nd edition. New York: John Wiley, 1987.
32. 32 Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
33. 33 Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 (suppl): 145-49.
34. 34 Apperloo AJ, de Zeeuw D, de Jong PE. The initial antiproteinuric effect of antihypertensive treatment predicts the effect of treatment on long-term renal function outcome. J Am Soc Nephrol 1992; 3: 279 (abstr).
35. 35 Petterson JC, Adler S, Bukart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-62.
36. 36 Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267-73.